Regional Chemotherapy: Overview

Surgical Oncology Clinics of North America

Volumn 17, Issue 4, 2008, Pages 709-730

  Muchmore, James H ^a   Wanebo, Harold J ^b  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Landmark Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CHLORMETHINE; CISPLATIN; CYTOTOXIC AGENT; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; IRINOTECAN; MELPHALAN; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; MULTIDRUG RESISTANCE PROTEIN 6; OXALIPLATIN; PLATINUM DERIVATIVE; THIOTEPA; UNINDEXED DRUG; VINCA ALKALOID;

ADVANCED CANCER; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CALCULATION; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM CANCER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FLOW RATE; HEMOFILTRATION; HEMOPERFUSION; HEPATIC ARTERY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYPERTHERMIC THERAPY; HYPOXIA; INFECTION; LIVER METASTASIS; MATHEMATICAL ANALYSIS; MAXIMUM PLASMA CONCENTRATION; MELANOMA; MICROENVIRONMENT; MULTIDRUG RESISTANCE; NONHUMAN; PERFUSION PRESSURE; REGIONAL CANCER CHEMOTHERAPY; REVIEW; SOLID TUMOR; THROMBOSIS; TISSUE NECROSIS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS;

EID: 49649102311     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.04.013     Document Type: Review

References (137)

1. Gilman A., and Philips F.S. Biological actions and therapeutic applications of B-chloroethyl amines and sulfides. Science 103 (1946) 409-415
2. Jacobson L.O., Spurr C.L., Barron E.S., et al. Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic disease and allied disorders of hemopoietic system. JAMA 132 (1946) 263-271
3. 2) therapy of neoplastic disease. Trans Assoc Am Physicians 60 (1947) 110-117
4. Klopp C.T., Alford T.C., Bateman J., et al. Fractional intra-arterial cancer chemotherapy with methyl-bis-amine hydrochloride. A preliminary report. Ann Surg 132 (1950) 811-832
5. Bierman H.R., Shimkin M.B., Byron Jr. R.L., et al. The effects of intra-arterial administration of nitrogen mustard (1950), Fifth International Cancer Congress, Paris p. 187-8
6. Ryan R.F., Krementz E.T., Creech O., et al. Selected perfusion of isolated viscera with chemotherapeutic agents using an extracorporeal circuit. Surg Forum 8 (1957) 158-161
7. Luck J.M. Action of p[DI(2-choroethyl)]-amino-L-phenylalanine on Harding-Passey mouse melanoma. Science 123 (1956) 983-984
8. Creech Jr. O., Krementz E.T., Ryan R.F., et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 148 (1958) 616-632
9. Krementz E.T. Regional perfusion. Current sophistication, what next?. Cancer 57 (1986) 416-432
10. Golomb F.M., Postel A.H., Hall A.B., et al. Chemotherapy of human cancer by regional perfusion. Report of 52 perfusions. Cancer 15 (1962) 828-845
11. Austen W.A., Monaco A.P., Richardson G.S., et al. Treatment of malignant pelvic tumors by extracorporeal perfusion with chemotherapeutic agents. N Engl J Med 261 (1959) 1045-1052
12. Stehlin J.S., Clark R.L., White E.C., et al. Regional chemotherapy for cancer: experiences with 116 perfusions. Ann Surg 151 (1960) 605-619
13. Jesse R.H. Technique of perfusion and infusion of head and neck. Cancer Chemotherapy Reports 10 (1960) 21-22
14. 2. Surg Forum 10 (1960) 77-79
15. Krementz E.T., and Ryan R.F. Chemotherapy of melanoma of the extremities by perfusion: fourteen years of clinical experience. Ann Surg 175 (1972) 900-915
16. Kokame G.M., Krementz E.T., and Creech Jr. O. Regional chemotherapy. In: Ulin A.W., and Gollub S.S. (Eds). Surgical bleeding, handbook for medicine, surgery and specialties (1966), McGraw Hill Book Co, New York 475-486
17. Sullivan R.D., Miller E., and Sykes M.P. Antimetabolite-metabolite combination cancer chemotherapy. Effects of intra-arterial methotrexate-intramuscular citrovorum factor therapy in human cancer. Cancer 12 (1959) 1248-1262
18. Sullivan R.D., Norcross J.W., and Watkins Jr. E. Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med 270 (1964) 321-327
19. Sullivan R.D. Chemotherapy in head and neck cancer. JAMA 217 (1971) 461-462
20. Vaupal P. Hypoxia in neoplastic tissue. Microvasc Res 13 (1977) 399-408
21. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9 (1990) 253-266
22. Muchmore J.H., and Arya J. Regional chemotherapy of cancer of the pancreas. In: Markman M. (Ed). Current clinical oncology: regional chemotherapy: clinical research and practice (1996), Humana Press Inc, Totowa (NJ) 101-125
23. Heldin C.H., Rubin K., Pietras K., et al. High interstitial fluid pressure: an obstacle in cancer therapy. Nat Rev Cancer 4 (2004) 806-813
24. Reddy L.H. Drug delivery to tumors: recent strategies. J Pharm Pharmacol 57 (2005) 1231-1242
25. Curti B.D. Physical barriers to drug delivery in tumors. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 2nd edition (1966), Lippincott-Raven Publishers, Philadelphia 709-719
26. Yang P.J., Thraik J.H., Ensminger W.D., et al. Perfusion scintigraphy (Tc-99m MAA) during surgery for placement of chemotherapy catheter in hepatic artery: concise communication. J Nucl Med 23 (1982) 1066-1069
27. Rice G.C., Hoy C., and Schimke R.T. Transient hypoxia enhances the frequency of DHFR gene amplification in Chinese hamster ovary cells. Proc Natl Acad Sci U S A 83 (1986) 5978-5982
28. Ross D.D., and Doyle L.A. Mining our ABCs: pharmacogenomic approach for evaluating transporter function in cancer drug resistance. Cancer Cell 6 (2004) 105-107
29. Goldstein L.J., Galski H., Fojo A., et al. Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 81 (1989) 116-124
30. Chabner B.A. Clinical strategies for cancer treatment: the role of drugs. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 4th edition (2006), Lippincott,Williams & Watkins, Philadelphia 1-14
31. Lee K., Belinsky M.G., Bell D.W., et al. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 58 (1998) 2741-2747
32. Litman T., Druley T.E., Stein W.D., et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58 (2001) 931-959
33. Bradbury P.A., and Middleton M.R. DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15 (2004) 421-426
34. Krementz E.T., Carter R.D., Sutherland C.M., et al. Regional perfusion of melanoma-a 35 year experience. Ann Surg 220 (1994) 520-535
35. Muchmore J.H., Carter R.D., and Krementz E.T. Regional perfusion for malignant melanoma and soft tissue sarcoma: a review. Cancer Invest 3 (1985) 129-143
36. Fraker D.L., and Eggermont A.M.M. Hyperthermic regional perfusion for melanoma of the limbs. In: Balch C.M., Houghton A.N., Sober A.J., et al. (Eds). Cutaneous melanoma. 4th edition (2003), Quality Medical Publishing, Inc, St. Louis (MO) 473-493
37. Brennan M.F., Singer S., Maki R.G., et al. Sarcomas of the soft tissues and bone. Section 1: soft tissue sarcoma. In: DeVita Jr. V.T., Hellman S., and Rosenberg S. (Eds). Cancer principles and practice of oncology. 7th edition (2005), Lippincott, Williams & Wilkins, Philadelphia 1581-1637
38. Eckman W.W., Patlak C.S., and Fenstermacher J.D. Critical evaluation of principles governing the advantages of intra-arterial infusions. J Pharmacokinet Biopharm 2 (1974) 257-285
39. Chen H.S., and Gross J.F. Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses. Cancer Treat Rep 64 (1980) 31-40
40. Collins J.M., and Dedrick R.L. Pharmacokinetics of anticancer drugs. In: Chabner B.A. (Ed). Pharmacologic principles of cancer treatment (1982), WB Saunders, Philadelphia 77-99
41. Collins J.M., and Supko J.P. Pharmacokinetics. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 4th edition (2006), Lippincott, Williams & Watkins, Philadelphia 31-44
42. Collins J.M. Pharmacokinetics and clinical monitoring. In: Chabner B.A., and Collins J.M. (Eds). Cancer chemotherapy: principles and practice (1990), Lippincott, Philadelphia 16-31
43. Sparreboom A., and Zamboni W.C. Topisomerase I-targeting drugs. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 4th edition (2006), Lippincott,Williams & Watkins, Philadelphia 371-413
44. Hofmann C., Buttenschoen K., Straeter J., et al. Pre-clinical evaluation of the activity of irinotecan as a basis for regional chemotherapy. Anticancer Res 25 (2005) 795-804
45. Chan K.K., Cohen J.L., Gross J.F., et al. Prediction of adriamycin disposition in cancer patients using physiologic, pharmacokinetic model. Cancer Treat Rep 62 (1978) 1161-1171
46. Erttmann R., Erb N., Steinhoff A., et al. Pharmacokinetics of doxorubicin in man: dose and schedule dependence. J Cancer Res Clin Oncol 114 (1998) 509-513
47. Matsushima Y., Kanazawa F., Hoshi A., et al. Time-schedule dependency of inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 14 (1985) 104-107
48. Alexander Jr. H.R., Kemeny N.E., and Lawrence T.S. Treatment of metastatic cancer: section 3: metastatic cancer to the liver. In: DeVita Jr. V.T., Hellman S., and Rosenberg S. (Eds). Cancer principles and practice of oncology. 7th edition (2005), Lippincott, Williams & Wilkins, Philadelphia 2352-2368
49. Mitchell R.B., Ratain M.J., and Vogelzang N.J. Experimental rationale for continuous infusion chemotherapy. In: Lokich J.J. (Ed). Cancer chemotherapy by infusion. 2nd edition (1990), Precept, Chicago 3-34
50. Ensminger W.D., and Gyes J.W. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10 (1983) 176-182
51. Ensminger W.D., and Gyes J.W. Regional cancer chemotherapy. Cancer Treat Rep 68 (1984) 101-115
52. Ensminger W.D. Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 29 (2002) 119-125
53. Link K.H., Aigner K.R., Kuehn W., et al. Prospective correlative chemosensitivity testing in high-dose intra-arterial chemotherapy for liver metastases. Cancer Res 46 (1986) 4837-4840
54. Link K.H., Aigner K.R., and Kessler D. In vitro chemosensitivity profiles of human malignancies for high-dose (regional) chemotherapy. Controversies in Oncology 29 (1988) 28-42
55. Schroy III P.C., Cohen A., Winawer S.J., et al. New chemotherapeutic drug sensitivity assay for colon carcinomas in monolayer culture. Cancer Res 48 (1988) 3236-3244
56. Kornmann M., Butzer U., Blatter J., et al. Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol 26 (2000) 583-587
57. Duda D.G., Jain R.K., and Willett C.G. Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25 (2007) 4033-4042
58. Yang A.D., Bauer T.W., Camp E.R., et al. Improving delivery of antineoplastic agents with antivascular endothelial growth factor therapy. Cancer 103 (2005) 1561-1570
59. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
60. Alexander Jr. H.R., Allegra C.J., and Lawrence T.S. Metastatic cancer to the liver: section 3: infusion therapy for hepatic metastases. In: DeVita Jr. V.T., Hellman S., and Rosenberg S. (Eds). Cancer principles and practice of oncology. 6th edition (2001), Lippincott, Williams & Wilkins, Philadelphia 2697-2702
61. Chan R., and Kerr D. Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003. Curr Opin Oncol 16 (2004) 378-384
62. Elaraj D.M., and Alexander H.R. Current role of hepatic artery infusion and isolated liver perfusion for the treatment of colorectal cancer liver metastases. Cancer J 10 (2004) 128-138
63. Kemeny N.E., and Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 352 (2005) 734-735
64. Eilber F., Giuliano A., Huth A., et al. Neoadjuvant chemotherapy, radiation, and limited surgery for high grade soft tissue sarcoma of the extremity. In: Ryan J.R., and Baker L.H. (Eds). Recent concepts in sarcoma treatment (1988), Kluwer, Dordrecht (The Netherlands) 115-125
65. Krementz E.T., and Kokame G.M. Regional chemotherapy of cancer of the head and neck. Laryngoscope 76 (1966) 880-892
66. Rabbani A., Hinerman R.W., Schmalfuss I.M., et al. Radiotherapy and concomitant intraarterial cisplatin (RADPLAT) for advanced squamous cell carcinomas of the head and neck. Am J Clin Oncol 30 (2007) 283-286
67. Kovacs A.F. Intra-arterial induction high-dose chemotherapy with cisplatin for oral and oropharyngeal cancer: long-term results. Br J Cancer 90 (2004) 1323-1328
68. Rasch C.R., Salverda G.J., Schornagel J.H., et al. Intraarterial versus intravenous chemoradiation for advanced head and neck cancer, early results of a multi-institutional trial. Int J Radiat Oncol Biol Phys 66 (2006) 51-52
69. Curt G.A., and Collins J.M. Clinical pharmacology of infusional chemotherapy. In: Lokich J.J. (Ed). Cancer chemotherapy by infusion. 2nd edition (1990), Precept, Chicago 35-41
70. Garnick M.B., Ensminger W.D., and Israel M. Clinical-pharmacological evaluation of hepatic arterial infusion of adriamycin. Cancer Res 39 (1979) 4105-4110
71. Hu E., and Howell S.B. Pharmacokinetics of intraarterial mitomycin C in humans. Cancer Res 43 (1983) 4474-4477
72. Dedrick R.L., Oldfield E.H., and Collins J.M. Arterial drug infusion with extracorporeal removal. Theoretical basis with particular reference to the brain. Cancer Treat Rep 68 (1984) 373-380
73. Oldfield E.H., Dedrick R.L., Yeager R.L., et al. Reduced systemic drug exposure by combining intra-arterial chemotherapy with hemoperfusion of regional venous drainage. J Neurosurg 63 (1985) 726-732
74. Muchmore J.H. Treatment of advanced pancreatic cancer with regional chemotherapy plus hemofiltration. Semin Surg Oncol 11 (1995) 154-167
75. Aigner K.R., Thiller H., Walther H., et al. Drug filtration in high-dose regional chemotherapy. Controversies in Oncology 29 (1988) 261-280
76. Muchmore J.H., Krementz E.T., Carter R.D., et al. Treatment of abdominal malignant neoplasms using regional chemotherapy with hemofiltration. Arch Surg 126 (1991) 1390-1396
77. Aigner K.R., and Gailhofer S. Celiac axis infusion for locally metastasized pancreatic cancer using spherex/mitoxantron microembolization and mitomycin C/chemofiltration. Regional Cancer Treatment 4 (1991) 3
78. Ravikumar T.S., Pizzorno G., Bodden W., et al. Percutaneous hepatic vein isolation and high-dose hepatic artery infusion chemotherapy for unresectable liver tumors. J Clin Oncol 12 (1994) 2723-2736
79. Ishida H., Makino T., Koayashi M., et al. Laparoscopic measurement of pancreatic blood flow. Endoscopy 15 (1983) 107-110
80. Aigner K.R., Walther H., and Link K.H. Isolated liver perfusion with MMC/5-FU-surgical technique, pharmacokinetics, clinical results. Controversies in Oncology 29 (1988) 229-246
81. Ng J.K., Urbanski S.J., Mangat N., et al. Colorectal liver metastases contract centripetally with response to chemotherapy. Cancer 112 (2008) 362-371
82. Wieberdink J., Benkuizen C., Braat R.P., et al. Dosimetry in isolated perfusion of the limbs assessment of perfused tissue volume and grading of toxic reactions. Eur J Cancer Clin Oncol 18 (1982) 905-950
83. Benckhuijsen C., Kroon B.B.R., van Geel A.N., et al. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of grug kinetics. Eur J Surg Oncol 14 (1988) 157-163
84. Kroon B.B.R. Regional isolation perfusion in melanoma of the limbs: accomplishments, unsolved problems, future. Eur J Surg Oncol 14 (1988) 101-110
85. Boddie A.W., Briele H., Krementz E.T., et al. A phase I study of melphalan in 40°C isolated limb perfusion using packed red blood cells and lactated Ringer's perfusate. Proceedings of the American Society of Clinical Oncology 11 (1992) 351
86. Song C.W., Park H.J., Lee C.K., et al. Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperthermia in tumor treatment. Int J Hyperthermia 21 (2005) 761-767
87. Fuhrman G.J., Fuhrman F.A., and Field J. Metabolism of rat heart slices with special reference to the effects of temperature and anoxia. Am J Physiol 163 (1960) 642-647
88. Begleiter A., Lam H.P., Grover J., et al. Evidence for active transport of melphalan by 2 amino acid carriers in LS1784 lymphoblasts in vitro. Cancer Res 39 (1979) 353-359
89. Giovanella B.C., Stehlin Jr. J.S., and Morgan A.C. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 36 (1976) 3944-3950
90. Miller R.C., Richards M., Baird C., et al. Interaction of hyperthermia and chemotherapy agents; cell lethality and oncogenic potential. Int J Hyperthermia 10 (1994) 89-99
91. Ko S.H., Ueno T., Yoshimoto Y., et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 12 (2006) 289-297
92. Chang S.Y., Evans T.L., and Alberts D.S. The stability of melphalan in the presence of chloride ion. J Pharm Pharmacol 31 (1979) 853-854
93. Briele H.A., Djuric M., Mortell T., et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. Cancer Res 45 (1985) 1885-1889
94. Mohamed F., Stuart O.A., Glehen O., et al. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor. Cancer Chemother Pharmacol 58 (2006) 719-724
95. Cavaliere R., Ciocatto E.C., Giovanella B.C., et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies. Cancer 20 (1967) 1351-1381
96. Stehlin Jr. J.S., Giovanella B.C., de Ipolyi P.D., et al. Results of hyperthermic perfusion for melanoma of the extremities. Surg Gynecol Obstet 140 (1975) 339-348
97. DiFilippo F., Calabro A., Giannarelli D., et al. Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 63 (1989) 2551-2561
98. Klaase J.M., Kroon B.B.R., van Geel A.N., et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 115 (1994) 39-45
99. 2 histogram) to skeletal muscle. Surgery 97 (1985) 278-284
100. Atkins M.B., Buzaid A.C., and Houghton A.N. Chemotherapy and biochemotherapy. In: Balch C.M., Houghton A.N., Sober A.J., et al. (Eds). Cutaneous melanoma. 4th edition (2003), Quality Medical Publishing, Inc, St. Louis (MO) 589-604
101. Coit D.G., and Ferrone C.R. Recurrent regional metastases. In: Balch C.M., Houghton A.N., Sober A.J., et al. (Eds). Cutaneous melanoma. 4th edition (2003), Quality Medical Publishing, Inc, St. Louis (MO) 439-448
102. Krementz E.T., Muchmore J.H., Carter R.D., et al. Multiple perfusions for melanoma. Melanoma Res 4 Suppl 1 (1994) 39-44
103. Lienard D., Lejeune F., and Evvalenko I. In transit metastases of malignant melanoma treated by high dose rTNFα in combination with interferon-gamma and melphalan in isolation perfusion. World J Surg 16 (1992) 234-240
104. Di Filippo F., Rossi C.R., Santinami M., et al. Hyperthermic isolation limb perfusion with TNF alpha in the treatment of in transit melanoma metastasis. In Vivo 20 (2006) 739-742
105. Cornett W., McCall L.M., Peterson R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor. J Clin Oncol 24 (2006) 4196-4201
106. Noorda E.M., Vrouenraets B.C., Nieweg O.E., et al. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion. Eur J Surg Oncol 32 (2006) 318-324
107. Thompson J.F., Kam P.C., Waugh R.C., et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 14 (1998) 238-247
108. Pennacchioli E., Deraco M., Mariani L., et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann Surg Oncol 14 (2007) 553-559
109. Eggermont A.M., Schrafford Koops H., Klausner J.M., et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224 (1996) 756-764
110. Grunhagen D.J., de Wilt J.H., Graveland W.J., et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 106 (2006) 1776-1784
111. Mulcare R.J., Solis A., and Fortner J.G. Isolation and perfusion of the liver for cancer chemotherapy. J Surg Res 15 (1973) 87-95
112. Skibba J.L., and Condon R.E. Hyperthermic isolation-perfusion in vivo of the canine liver. Cancer 51 (1983) 1303-1309
113. Quebbeman E.J., Skibba J.L., and Petroff Jr. R.J. A technique for isolated hyperthermic liver perfusion. J Surg Oncol 27 (1984) 141-145
114. Aigner K., Walther H., Tonn J., et al. First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary. Recent Results Cancer Res 86 (1983) 99-102
115. Lise M., Pilati P., Da Pian P., et al. Hyperthermic isolated liver perfusion for unresectable liver cancers: pilot study. J Chemother 16 Suppl 5 (2004) 37-39
116. Mocellin S., Pilati P., Da Pian P., et al. Correlation between melphalan pharmacokinetics and hepatic toxicity following hyperthermic isolated liver perfusion for unresectable metastatic disease. Ann Surg Oncol 14 (2007) 802-809
117. Marinelli A., de Brauw L.M., Beerman H., et al. Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases to the liver. Jpn J Clin Oncol 26 (1996) 341-350
118. Dedrick R.L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12 Suppl 4 (1985) 1-6
119. Meyers C.E., and Collins J.M. Pharmacology of intraperitoneal chemotherapy. Cancer Invest 1 (1983) 395-407
120. Grenn J.L. 5-Fluoropyrimidines. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 4th edition (2006), Lippincott, Williams & Watkins, Philadelphia 124-182
121. Markman M. Intraperitoneal drug delivery of antineoplastics. Drugs 61 (2001) 1057-1065
122. Sugarbaker P.H., and Jablonski K.A. Prognostic features in 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221 (1995) 124-132
123. Elias D., Blot F., El Otmany A., et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92 (2001) 71-76
124. Markman M. Role of intraperitoneal chemotherapy in the front-line setting. J Clin Oncol 21 Suppl 10 (2003) 145s-148s
125. de Bree E., Rosing H., Michalakis J., et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 32 (2006) 666-670
126. Fujimoto S., Shresta R.D., Kokubun M., et al. Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for advanced gastric cancer. Ann Surg 212 (1990) 592-596
127. Yan T.D., Black D., Sugarbaker P.H., et al. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for respectable gastric cancer. Ann Surg Oncol 14 (2007) 2702-2713
128. Los G., Mutsaers P.H., van der Vijgh W.J., et al. Direct diffusion of cisplatinum in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 48 (1989) 3380-3384
129. van Ruth S., Verwaal V.J., Hart A.A., et al. Heat penetration in locally applied hyperthermia in the abdomen during intra-operative hyperthermic intraperitoneal chemotherapy. Anticancer Res 23 (2003) 1501-1508
130. Jayne D.G., Fook S., Loi C., et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89 (2002) 1545-1550
131. Yan T.D., Sim J., and Morris D.L. Selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and perioperative intraperitoneal chemotherapy. Ann Surg Oncol 14 (2007) 1807-1817
132. Elias D., Raynard B., Farkhondeh F., et al. Peritoneal carcinomatosis of colorectal origin: long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol 30 (2006) 1200-1204
133. Verwaal V.J., van Ruth S., de Bree E., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21 (2003) 3737-3743
134. Pinkpank Jr. J.F. Peritoneal carcinomatosis. In: DeVita Jr. V.T., Hellman S., and Rosenberg S. (Eds). Cancer principles and practice of oncology. 7th edition (2005), Lippincott, Williams & Wilkins, Philadelphia 2237-2246
135. Loggie B.W., Fleming R.A., McQuellon R.P., et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67 (2001) 999-1003
136. Yan T.D., Edwards G., Alderman R., et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma-a prospective study of 70 consecutive cases. Ann Surg Oncol 14 (2007) 515-525
137. Baratti D., Kusamura S., Martinetti A., et al. Circulating CA125 in patients with peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 14 (2007) 500-508